The “Great Debate” at Immunotherapy Bridge 2022, Naples, November 30th–December 1st, 2022
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource, 1 online resource.
- Language
-
Englisch
- Bibliographic citation
-
The “Great Debate” at Immunotherapy Bridge 2022, Naples, November 30th–December 1st, 2022 ; volume:21 ; number:1 ; day:22 ; month:4 ; year:2023 ; pages:1-10 ; date:12.2023
Journal of translational medicine ; 21, Heft 1 (22.4.2023), 1-10, 12.2023
- Creator
-
Ascierto, Paolo A.
Brentjens, Renier
Khleif, Samir N.
Odunsi, Kunle
Rezvani, Katayoun
Ruella, Marco
Sullivan, Ryan J.
Fox, Bernard A.
Puzanov, Igor
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12967-023-04117-3
- URN
-
urn:nbn:de:101:1-2023090209090406139725
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:48 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Ascierto, Paolo A.
- Brentjens, Renier
- Khleif, Samir N.
- Odunsi, Kunle
- Rezvani, Katayoun
- Ruella, Marco
- Sullivan, Ryan J.
- Fox, Bernard A.
- Puzanov, Igor
- SpringerLink (Online service)
Other Objects (12)
The “Great Debate” at Melanoma Bridge 2022, Naples, December 1st–3rd, 2022
Perspectives in Immunotherapy: meeting report from Immunotherapy Bridge (Naples, November 30th–December 1st, 2022)
Adjuvant therapy of melanoma with interferon: lessons of the past decade
Melanoma: the role of surgery in the era of new therapies
What have we learned from cancer immunotherapy in the last 3 years?
Combination therapy: the next opportunity and challenge of medicine
Checkpoint inhibitors in melanoma and early phase development in solid tumors: what’s the future?
The great debate at “Melanoma Bridge 2018”, Naples, December 1st, 2018
Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 1st–3rd, 2022—Naples, Italy)
Melanoma: A model for testing new agents in combination therapies
Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application
World-Wide Immunoscore Task Force: meeting report from the “Melanoma Bridge”, Napoli, November 30th–December 3rd, 2016
The “Great Debate” at Melanoma Bridge 2022, Naples, December 1st–3rd, 2022
Perspectives in Immunotherapy: meeting report from Immunotherapy Bridge (Naples, November 30th–December 1st, 2022)
Adjuvant therapy of melanoma with interferon: lessons of the past decade
Melanoma: the role of surgery in the era of new therapies
What have we learned from cancer immunotherapy in the last 3 years?
Combination therapy: the next opportunity and challenge of medicine
Checkpoint inhibitors in melanoma and early phase development in solid tumors: what’s the future?
The great debate at “Melanoma Bridge 2018”, Naples, December 1st, 2018
Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 1st–3rd, 2022—Naples, Italy)
Melanoma: A model for testing new agents in combination therapies
Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application
World-Wide Immunoscore Task Force: meeting report from the “Melanoma Bridge”, Napoli, November 30th–December 3rd, 2016
The “Great Debate” at Melanoma Bridge 2022, Naples, December 1st–3rd, 2022
Perspectives in Immunotherapy: meeting report from Immunotherapy Bridge (Naples, November 30th–December 1st, 2022)
Adjuvant therapy of melanoma with interferon: lessons of the past decade
Melanoma: the role of surgery in the era of new therapies
What have we learned from cancer immunotherapy in the last 3 years?
Combination therapy: the next opportunity and challenge of medicine
Checkpoint inhibitors in melanoma and early phase development in solid tumors: what’s the future?
The great debate at “Melanoma Bridge 2018”, Naples, December 1st, 2018
Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 1st–3rd, 2022—Naples, Italy)
Melanoma: A model for testing new agents in combination therapies
Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application